Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron L Boster

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Multiple Sclerosis and Related Disorders|January 21, 2021
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 yearsAnn D Bass, Rafael Arroyo, Aaron L Boster, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Pageof 2